Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well as ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

AC Immune (NASDAQ: ACIU) isn't a familiar name to many investors, but that might be changing. The Switzerland-based biotech ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...